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A 3.1
Outcome Assessment Methodology in Peripheral Arterial Disease
Impetus for Outcomes Research
Although the value of lifesaving therapies is boldly displayed in both the medical and lay press,
most medical treatment provided in the developed countries is directed toward improvement in
quality of life. Interventions for claudication and CLI are examples of therapies directed toward
the relief of symptoms and improvement in quality of life. The goal of all such interventions is
to reduce the adverse impact of an illness or disorder on the patient's life and improve the
patient's sense of well-being and productivity. A~ the costs of health care continue to spiral
upward, governments and third-party payers are seeking to contain costs by limiting reimburse-
ment to those therapies proven to be effective, either in saving lives or improving quality of life.
Ultimately, the decision to advocate a treatment, and the decision by payers and regulatory bod-
ies for reimbursement involves a trade-off between the additional costs incurred and effective-
ness gained by performing that treatment. 1
Multiple studies have been published reporting the experience of centers on the short and long-
term results of performing interventions for PAD. Unfortunately, these studies are frequently
difficult to compare and to apply directly to patient management. This is attributable to the dif-
ferences in study populations with respect to disease severity and risk factors, differences in
reporting methods such as including versus excluding technical failures in the patency results,
and the lack of outcome data relevant to the patient such as walking ability and quality of
life.2,3,4,5,6 In terms of the levels of evidence according to the Sackett classification, these stud-
ies all fall in the lowest level category V.
To permit delineation of appropriate reporting criteria, the Ad Hoc Committee on Reporting
Standards of the Vascular Societies established categories of vascular disease commonly seen in
clinical practice. 2,5 These criteria have served to improve the published data available to tlle vas-
cular specialist for the diagnosis and treatment of vascular disease and have led the way to a
standardized methodology for reporting the results of treatment. Such standardization of
methodology is important not only for current therapies but also for the assessment of new
technologies and techniques in this time of rapid technological proliferation. This fact has been
recognized by governmental regulatory agencies and payers.
To evaluate therapeutic effectiveness requires the use of outcomes measures that assess factors
that affect patients directly (eg, physical and social functioning and pain) ramer than only clini-
cal measures (eg, laboratory test scoresj.f ABPIs, for example, are typically of interest to the.
physician because they are measurable semi-objective outcomes of the intervention performed.
Ultimately, patients are not interested in their ankle pressures or patency of their arteries but
rather how far they can walk, limb salvage, and surviving any procedure performed-measures
of overall effectiveness (Table 7). The assessment of a therapeutic endeavor by outcome mea-
sures and clinical parameters can yield different results.
Table 7. Examples of outcome measures of effectiveness
Technical success of revascularization procedure
Death as a result of rcvascularization procedure
Short- and long-term morbidity as a result of revascularization procedure
Change in mean ankle-brachial indices
Survival/life expectancy
Amputation-free survival/lite expectancy
Quality-adjusted survival/life expectancy
Generic health status (eg, medical outcomes study short form questionnaire with 36 items [SF-36])
Disease-specific measures of functional status (eg, walking impairment questionnaire lWIQJ, walking distance)
Valuational measures/utility assessment (eg, visual rating scale [VRS], Health Utilities Index [HUI], European quality of life
instrument [EuroQol])
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A 3.2 Outcome Measures of Effectiveness
The outcome after treatment of PAD should focus on the degree of change in dinical and func-
tional status in relation to the pretreatment starus.f After surgical and percutaneous procedures,
a number of intermediate outcomes potentially related to the procedure are important in assess-
ing the overall outcome after treatment. These arc, for example, technical success of the proce-
dure and procedural complications, resulting in either short- or long-term morbidity.
Furthermore, for decision -making purposes it is necessary to distinguish the long-term and
short-term effects of complications on life expectancy, quality of life, or costs . Systemic compli-
cations (eg, MI, stroke) generally have important short- and long-term effects, whereas local
complications (eg, hematoma, pseudoaneurysm, wound infection) generally only have short-
term effects.
A 3.2.1 Technical Success
Technical success is particularly relevant to percutaneous interventions. Without technical suc-
cess, one cannot expect a clinically successful outcome, and technical success is not always
achieved. Furthermore, immediately after percutaneous angioplasty, some measurement is
required to determine whether further intervention is necessary during the same procedure in
the form of angioplasty with a larger balloon or stent placement. Angiographic definitions of
technical success after angioplasty have a poor reproducibility. A high interobserver variability
has been demonstrated between radiologists performing the procedure and an independent
reader.? Furthermore, the angiographic residual stenosis correlates poorly with the postproce-
dural intraarterial pressure gradicnt.? Measuring pressure gradients across a treated segment,
with pharmacological vasodilatation, is currently the most widely used measure of technical suc-
cess after percutaneous angioplasty. Intravascular ultrasound is potentially the most accurate
method of detecting a technical successful result in large vessels. Technical failures should be
included in the assessment of overall outcome.
A 3.2.2 Procedural Complications
One of the main problems with determining and reporting complications is that it can be diffi-
cult to distinguish procedural from nonprocedural mortality and morbidity. The distinction can
be very subjective. Thus, by convention, 30-day mortality and morbidity rates should be report-
ed. It would be useful to define complications as any untoward event following the procedure
with either a lasting negative effect (eg, MI, death) or requiring a change in management (eg,
extra day in hospital of observation, blood transfusion). Using this definition, for example,
minor hematomas after angioplasty that have no consequence are not counted as a complica-
tion. A hematoma is only counted as a complication if the patient is observed longer, recuper-
ates longer, requires a blood transfusion, or requires evacuation of the hematoma. There are
multiple proposed definitions of minor and major complications.
A 3.2.3 Criteria for Success
The short- and long-term success rates after an intervention depend on the definition used for
success .f For example, van Andel et altO reported far higher than average results after iliac PTA
because they used the presence of a palpable common femoral artery (CFA) pulse as a measure
of success. Conversely, Johnston et al,ll by using the criteria of clinical improvement plus an
increased ABPI, reported lower than average results because subsequent occlusive events distal
to the percutaneous transluminal angioplasty (PTA) (typically superficial femoral artery [SFA]
occlusion) were wrongly included as PTA failure. Table 8 illustrates how patency results may
vary by applying different criteria of a successful outcome to the same data.
ABPI is commonly used as an objective measure of success but may be influenced by disease, or
treatment, at other sites. Furthermore, exercise or drug regimens that improve walking distance
do not necessarily improve ABPI or blood flow.l-' The results of infrapoplitcal PTA are very dif-
ficult to ascertain because this is usually accompanied by treatment at other sites. Furthermore,
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Table 8: Different patency rates obtained by applying criteria of a successful outcome to exactly the same
data12
Criteria used to measure successful outcome
8. Thigh.brachial index >0.1
t>. Thigh.brachial index >0.1 plus no clinical deterioration
t>. Ankle.brachial index >0.1
8. Ankle.brachial index >0.1 plus no clinical deterioration
t>. Ankle.brachial index plus clinical improvement
Patency rate (%)
89
79
68
58
54
some early reports of surgical series, when compared with audited data, were unduly opti-
mistic.!4,15 Similarly, it is well known that results of personal or institutional series are often sig-
nificantly better than those from strictly controlled and audited multicenter trials.
Clinical success in the surgical and radiological literature is defined as some combination of
symptomatic improvement and objective hemodynamic success. After the first publication of the
reporting standards for surgical and percutaneous interventions, many authors combined symp-
tomatic criteria and objective hemodynamic criteria with an 'or.' This would have been classified
as at least +1 level of improvement- and implies using a very lenient criteria for success. The
revised reporting standards recommend a more stringent success criteria (at least +2 level of
improvement), stating that both symptomatic improvement 'and' objective hemodynamic
improvement are required for success.f A distinction is made between i) clinical success as deter-
mined by symptomatic improvement 'and' objective hemodynamic improvement of the entire
limb, ii) hemodynamic success, which applies to objective improvement of the entire limb, and
iii) patency, which applies to the revascularized or bypassed segment only.f Furthermore, it is
important to distinguish primary, assisted primary, and secondary patency.
Primary patency implies uninterrupted patency following only the procedure being evaluated.
Assisted primary patencyis used in reporting surgical interventions and implies that cases under-
going a revision of the graft before graft occlusion, that is, prophylactic interventions, are not
counted as failures if the revision salvages the graft. Secondary patency implies patency following
the initial procedure or following a reintervention to restore patency of an occluded graft or
vessel. After either a surgical or endovascular procedure, secondary patency implies the need in
some patients for reopening of tile treated segment by a second intervention. (See also A 3.2.9,
Patency, p S42.)
Apart from measuring symptomatic improvement, objective improvement, and patency, out-
comes directly relevant to the patient should be measured. Numerous instruments have been
developed to measure health-related quality of life that are useful in this regard. A distinction
should be made between the descriptive and valuational instruments. Whereas descriptive instru-
ments provide scores for quality of life on various dimensions, valuational measures provide a
quantitative assessment of quality of life. Descriptive instrumentsinclude generic and disease-spe-
cific health status questionnaires. These yield scores describing the respondent's mobility, fiinc-
tioning, mental health, and overall well-being. Valuational instruments yield holistic numerical
values of the quality of life on a scale from 0.0 (usually anchored as death) to 1.0 (usually
anchored as perfect health), Such values are required in cost-effectiveness analysis by health care
purchasers when deciding whether a particular gain in effectiveness justifies tile additional cost,
for example, use of stent placement rather than, for example, balloon angioplasty alone (see also
A 4, Economic Aspects of PAD, p 545).
Studies evaluating the relationship between various outcome measures have shown moderate to
poor correlation. For example, the ABPr does not correlate well with the degree of exercise
impairment, and changes in ABPI do not correlate well with changes in walking distance.lc The
correlation between various health status questionnaires and walking distance or ABPI has been
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demonstrated to be poor to moderate.l 7,18,19 The relationship between ABPI or angiographic
findings and quality-of-life measures also appears to be weak.1 0 Similarly, the relationship
between descriptive quality-of-life measures and valuational measures in patients with PAD
appears weak.2l These results seem to imply that "success" of an intervention is a multidimen-
sional entity requiring consideration of traditionally used measures ofmedical effectiveness (eg,
ABPI, patency), walking ability of the patient (functional status either measured directly or with
the walking impairment questionnaire), descriptive health status measures (eg, SF-36), a.nd mea-
sures valuing quality of life (eg, HUI, EuroQol).
Recommendation 1: Outcome measures in peripheral arterial disease
In determining the baseline severity of disease and changes in response to treatment,
the following outcomes should be documented:
• Objective/hemodynamic status of the limb
• After revascularization: patency of the revascularized segment
• Symptomatic status of the limb
• General quality of life of the patient
• Value or utility assessment of quality of life of the patient
Outcome Measures should reflect a standardized reporting time frame similar to that recom-
mended by the SVS/ISCVS for endovascular procedures:
• Initial outcome = 30 days after procedure
• Short-term = 1 to 12 months, but statistically valid data" at least to 6 months
• Intermediate-term = 6 to 24 months, but statistically valid data" beyond 1 year
• Long-term = statistically valid data" beyond 2 years
.. Life Table or Kaplan-Meier projections with standard error not exceeding 10% at this point.
Critical Issue 1: Relationship between different outcome measures
Methodological work is required to understand the relationship between traditionally
used measures of medical effectiveness (eg, ABPI, pateney), walking ability of the
patient (eg, walking distance or walking impairment questionnaire), descriptive health
status measures (eg, SF-36), and measures valuing quality of life (eg, HUI, EuroQol),
especially in severe ischemia.
A 3.2.4 Objective Outcome Measures
As an objective measure of improvement, hemodynamic criteria are commonly used. An increase
in the ABPI of more than 0.15 (as stand-alone criteria; 0.10 if combined with symptomatic cri-
teria) or an increase in ABPI to more than 0.90 has been recommended as an objective measure
of success.f If the ABPI cannot be measured accurately, for instance, in diabetic patients, the toe
pressure may be substituted. The term hemodynamic failure indicates a lack of significant hemo-
dynamic improvement as determined by an increase in ABPI, using distal pressures, regarcl1ess of
whether the artery is patent. In evaluating exercise and drug regimens for claudication, however,
the mean ABPI generally does not improve in spite of improvements in exercise performance
and functional starus.U To enable comparison between the results of revascularization and exer-
cise or medical treatments, every clinical trial for IC should evaluate the severity and. impact of
claudication using a treadmill exercise test (see Recommendation 43, p SI32).
A 3.2.5 Symptomatic Outcome Measures
Symptom severity and outcome of an intervention can be judged by classifying patients' symp-
toms on a scale. The two most well-known classifications are the Fontaine stages and
Rutherford's categories, which is currently recommended to determine significant clinical
improvement (Table 9).s Category 0 indicates the asymptomatic state; category 1, mild; 2,
moderate claudication; and 3, severe claudication; 4, ischemic rest pain; 5, minor tissue loss; and
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Table 9. Classification of peripheral arterial disease: Fontaine's stages and Rutherford's categories
Fontaine Rlltherford
Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild claudication I 1 Mild claudication
IIb Moderate-severe I 2 Moderate claudication
claudication I 3 Severe claudication
III Ischemic rest pain II 4 Ischemic rest pain
III 5 Minor tissue loss
IV Ulceration or gangrene III 6 Major tissue loss
6, major tissue loss. Objective criteria are also part of the overall published clinical classification
scheme and are based on the subject's ability to complete a treadmill exercise test. However, the
objective criteria of improvement should probably be considered separately to avoid confusing
"symptomatic improvement" and "objective improvement." Symptomatic improvement requires
an upward shift of at least one category on the scale except for those with actual tissue loss (cat-
egory 5) who must at least improve to a level of claudication to be considered improved.
A 3.2.6 Disease-Specific Health Status Questionnaires
Probably the oldest disease-specific questionnaire for intermittent claudication is the one devel-
oped by Rose. 22,23 Although not very sensitive, this questionnaire has been widely used in iden-
tifying patients with claudication.24,25 The WIQ is a disease-specific instrument developed to
characterize walking ability through a questionnaire as an alternative to treadmill testing. This
has been demonstrated to be useful in intermittent claudication.w It includes questions about
the degree of pain, aching, or cramps, the reason for the difficulty walking, walking distance,
walking speed, and stair climbing. It is proposed that a disease-specific health status question-
naire be used to document symptomatic status. Currently, there is no disease-specific question-
naire for severe ischemia.
To assess the patient's activity level, the peripheral arterial disease Physical ActivityRecall (PAD-
PAR) questionnaire may be used; this is a measure ofhabitual physical activity and provides a
global estimate of the total energy expended.27 A combined generic- and disease-specific ques-
tionnaire was developed by McDaniel et al,24 using items from several previously developed and
tested instruments, including the instrumental activities of daily living questionnaire. The
Spitzer Ql.-index, which was originally designed for application in oncology, has also been used
for measuring quality of life in patients with PAD. 28,29
Recommendation 2: Symptomatic outcome measures
To measure baseline and changes in symptomatic disease-specific health status, a disease-
specific health status questionnaire should be used, such as the Walking Impairment
Questionnaire (WIQ).
Critical Issue 2: Symptomatic outcome measures in acute and critical limb ischemia
There is a need for a validated disease-specific questionnaire for patients with acute or
critical limb ischemia.
A 3.2.7 Generic Health Status Questionnaires
Several generic instruments are useful in gathering information regarding quality of life. Though
somewhat different in format, each of these instruments attempts to obtain important data in
four major categories: functional status assessment, perceived health, psychological well-being,
and role function. Functional status assessment is directed toward determining how well the
patient can perform basic physical tasks, such as the ability to climb stairs, read a newspaper, or
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hold a pen. Perceived health identifies how healthy a patient believes he or she is and how much
a patient worries about his or her health. PsychololJicalll'cll-beinp focuses on the extent to which
patients become distressed, anxious, or depressed about their illnesses and associated treatments,
Role function. evaluation is directed toward the assessment of the impact of a patient's disorder
on his or her ability to work and perform his or her obligatory duties, such as care for his or her
family, and on his or her resources.
Studies evaluating health-related quality of lite have demonstrated that patients with PAD have
poorer scores on various measures of functional health and well-being compared with patients of
similar age and sex without the disease.20,21 The Medical Outcomes Study Short-Form 36 (Sf-
36) is a generic health status questionnaire that appears to be useful in evaluating quality of life
in patients with PAD.19,21,30 The SF-36 assesses eight health dimensions-physical functioning,
social functioning, role limitations due to physical problems, role limitations due to emotional
problems, pain, mental health, energy, general health perception-and a one-item question:
change in health during the past year.
For each Sf-36 dimension, item scores are coded, summed, and transformed onto a scale from
o to 100, with 100 being thc highest score. The RAND-36 (RAND Corporation) and the SF-
36 are practically the same and have identical items, but the scoring is slightly different for the
dimensions pain and general health pcrception.s! The dimensions physical functioning and role
limitations due to physical functioning and pain are especially affected by the presence of PAD
(Figure 19). At least 8 of the 36 questions can be considered directly relevant for the evaluation
of PAD, including questions about walking distance, the ability to climb stairs, and pain. The
SF-36 (and RAND-36) is a generic measure that has been used in multiple settings and validat-
ed across a wide spectrum of diseases; therefore comparison with the outcomes of patients with
Figure 19: Quality of life assessed with the RAND 36-Itclll Health Survey 1.0 (mean scores with confidence intervals)
in patients with peripheral arterial disease compared with the general population. Reproduced from Mcd Dccis Making
1996;16:217-225,
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other diseases and comparison with the healthy population are possible (Figure 19). Both the
RAND-36 and SF-36 have been translated into several languages, and both ca.n be completed
by the patients themselves.
The Functional Status Questionnaire and instrumental activities of daily living have also been
applied in the assessment of PAD.24, 32 The Sickness Impact Profile (SIP) has been used in the
assessment of PAD and in the United States in a randomized controlled clinical trial comparing
the outcome of PTA and bypass surgery for PAD.18,33,34,35 The Nottingham Health Profile
(NHP) has been used in the United Kingdom in a study comparing PTA with medical treat-
ment.36,37,38 Both the SIP and NHP are fairly lengthy questionnaires. In measuring health-
related quality of life, a number of issues, including validity, reliability, and feasibility, need to be
considered. Such criteria have been proposed by various scientific groups (Association for
Pharmacoeconomics and Outcomes Research [APOR], 1996; European Organisation for
Research and Treatment of Cancer [EORTC]) and are increasingly requested by guidelines
(Canadian Coordinating Office for Health Technology Assessment [CCOHTA], 1996; Gold et
ai, 1996).
The following criteria should be applied when choosing a measure of health-related quality of
life, in particular for multinational clinical trials:
• Validity (the extent to which a technique measures what it is supposed to measure)
• Reliability (stability of scores)
• Feasibility (burden tor the respondent and investigator)
• Responsiveness (likelihood of detecting a clinically important change or treatment effect)
• Cultural and language adaptations (standardized translations, linguistic evaluations, psychomo
tor validations, attention to cultural issues)
Recommendation 3: Generic health status outcome measures
Until better instruments are developed, if general health status is to be measured, the
Short Form 36 (SF-36 or RAND-36) questionnaire is recommended to measure base-
line and changes in generic health status.
A 3.2.8 Valuing Health-Related Quality of Life and Utility Assessment
To determine whether the additional costs incurred by performing an intervention are justified
compared with the effectiveness gained, the gain in effectiveness needs to be valued) The rec-
ommended approach is to express effectiveness in quality-adjusted life years (QALYs), which is a
composite value combining both length and quality of life.1 In estimating QALYs, every year
spent in full health is counted as a full year. Years spent in less than full health are counted as
some fraction of a year, as determined by the value of the health state. For example, if a subject
enjoys 2 years of full health followed by 6 years in a health state with pain valued at 50%of the
values offull health, the patients would have had 5 QALYs (ie, 2 + 50% of 6). Thus, calculating
QALYs requires quantifying the quality of life in the various health states. A few studies have
determined values for various health states related to PAD. Such holistic values reflect the rela-
tive value of life with the disease compared with perfect health. They may be expressed, for
example, on a scale from zero to I, where zero is equivalent to death and 1 equals perfect
health comparable to contemporaries. These measures include the time trade-off, standard gam-
ble, rating scale, visual analog scale, EuroQol, HUI, and Quality of Well-Being
scale.39,40,41,42,43,44
In the time trade-off, patients are asked to choose between trading life expectancy to avoid mor-
bidity versus living longer with morbidity. In the standardgamble, patients are asked to choose
between taking a risk of immediate death to avoid the morbidity of less desirable health states
versus the certainty of living with morbidity. Both the time trade-off and standard gamble deter-
mine the patient's point of indifference between trading life expectancy or taking risk, respec-
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tively, and living with morbidity. The rating scale and visual analog methods require subjects to
directly value health states on a scale from zero to 100, zero generally being equivalent to death
and 100 perfect health, by either responding with a number or placing a mark on a line.
The Health Utility Index) Q;tality of Well-Being Scale, and EuroQpI are all multi-attribute utility
instruments that classify patients into one of many health states determined by their responses to
questions on several dimensions (or attributes) of health. For each health state, a value can be
calculated using a known formula that reflects how important each dimension is considered.
This formula was derived using multi-attribute utility theory and determined by obtaining val-
ues from the general population based on generic scenarios describing the health state. 4 3
Typically, these multi-attribute values for claudication range from 0.60 to 0.85, from 0.30 to
0.45 for rest pain, and from 0.20 to 0.60 for amputation.21,45 The obtained values depend on
the questionnaire used. The standard reference gamble generally yields the highest values, fol-
lowed by the time trade-off, rating or visual analog scale, and then the HUI. These differences
are due to attitudes toward risk, how scales are interpreted, and whether the values are obtained
from patients or the general public.
In general, the recommended perspective for performing a cost-effectiveness analysis is socictal.!
implying that values for such analyses should be obtained from the general public. Both the
HUI and the EuroQol provide known societal values for generic health states, implying that one
only needs to determine the patients' generic health states. In general, the HUI is recommend-
ed for obtaining values from the societal perspective. The EuroQoL can provide similar values
with fewer questions and is easier to administer but discriminates less well between health states,
is less sensitive to changes, and is not based on standard reference gamble utilities.46
Alternatively, disease-specific scenarios of health states can be formulated based on the patients'
experiences and a general population asked to value these scenarios, which for amputation espe-
cially yielded lower values than when the scenario was based on generic scenarios.f?
Recommendation 4: Value/utility assessment
Valuing health-related quality of life is only necessary in the setting of a clinical trial
with a cost-effectiveness study. The Health Utilities Index or EuroQol are recommended
to obtain a single global value from the societal perspective based on the health status of
the patient group under consideration. In daily clinical practice, one verbal rating scale
question, or a visual analog scale question, can be used to obtain a global value for
quality of life from the patient's perspective.
A 3.2.9 Patency
Determining patency is required for presentation of the results ofpercutaneous and surgical
interventions in scientific journals. Patency should always be based on objective findings and
should be distinguished from symptomatic and objective improvement as already defined.
Whereas symptomatic and objective improvement both apply to the entire limb, patency applies
to the revascularized or bypassed segment only. For patency, anyone of five criteria must be
met, of which the following two are the most relevantf:
• Demonstrably patent by vascular imaging using angiography, (color-guided) Duplex ultra
sound or magnetic resonance angiography
• Maintenance of achieved improvement in the appropriate segmental limb pressure index;
that is, not more than 0.10 below the highest postoperative index. If a drop of more than
0.10 is measured, imaging proof of patency is required. The most appropriate pressure
index is the one at the next level beyond the revascularized segment or distal anastomosis.
A graft or revaseularized segment is considered to have "primary" patency if it has had uninter-
rupted patency with either no procedure performed on it or a procedure (eg, transluminal dila-
tion or a proximal or distal extension to a graft) to deal with disease progression in the adjacent
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native vessel. Thus, the only exceptions that do not disqualify the graft for primary patency are
procedures performed for disease beyond the graft or the revascularized segment. Dilation or
minor revisions performed for stenoses, dilation, or other structural defects, or closing missed
arteriovenous (AV) fistulas in an in situ vein bypass, before occlusion, do not constitute excep-
tions, because they are intended to prevent eventual failure of the revascularization procedure.
The additional designation of "assisted primary patency" applies to the special situation in which
patency was never lost but rather maintained by prophylactic intervention. If patency of the
revascularized segment is restored after occlusion, by thrombectomy, thrombolysis, or translu-
minal angioplasty, or if any problems with the revascularized segment itself, for example, the
graft or one of its anastomoses, require revision or reconstruction, all must be listed under "sec-
ondary" patency. In the case of a graft, a "redo" or secondary reconstruction does not con-
tribute to secondary patency, wnless most of the originalgraft and at least one anastomosis are
retained in continuity. Although the above definitions were originally developed for bypass
grafts, they now can be equally applied to any type of revascularized segment, such as
endarterectomy, PTA, or stenting, but it is generally agreed that the entire anatomic arterial seg-
ment should be considered as one, much like a bypass graft.
Reconunendation 5: Deftnition of patency
Vascular imaging is the reference standard for determining patency. In its absence,
patency may be defined as maintenance of achieved hemodynamic improvement in the
relevant segment; ie, not more than 0.10 below the highest postoperative index. If a
drop of more than 0.10 is measured, proof of patency with vascular imaging is required.
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